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randomized clinical trialsSir,
I read with interest the paper entitled, “Acute effects of
indacaterol on lung hyperinflation in moderate COPD:
a comparison with tiotropium”, that has been recently
published on line in Respiratory Medicine(1). As I have had
in the past a recurrent exchange of opinions with some of
the Authors on the spirometric criteria for defining airflow
limitation,2e6 and particularly on the relative value of the
fixed ratio (FR) FEV1/FVC < 0.7 proposed by the GOLD
initiative7 versus the Lower Limit of Normal (LLN) of FEV1/
VC,8 I carefully read the entry criteria of the study and I
was surprised to verify that, similarly to previous studies,9
the same Authors, who heavily criticize the GOLD criteria
to the point of requesting the endorsement not only of the
Italian “scientific” respiratory societies but also of the
Italian Ministry of Health10 continue to use the GOLD
criteria in their clinical trials and practice.1,9 I did notice
that in this specific study1 they used both the post-
bronchodilator FEV1/FVC < 0.7 and the LLN of FEV1/VC
related to predicted values,8 but unfortunately they
omitted to mention whether the values were pre- or post-
bronchodilators, and whether the predicted values used
to express the results were pre- or post-bronchodilator. As
the methods were not described in details in the paper, I
went to the study protocol11 and I found that the LLN of
FEV1/VC was not mentioned in the protocol nor in the
amendments, and that the only entry criteria for the study
were the GOLD criteria.7 As I stated in previous corre-
spondence,2,4,6 I do not believe that the use of one crite-
rion or the other creates a major problem, but I have to
admit that my opinion is not based on evidence. I think it
would be interesting to give to the Authors the opportunity
to provide this evidence, by publishing the individual data
of FR and LLN not reported in the paper, and comment on
discrepancies, if any!
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